Austria’s Medicine Shortage Worsens as EU Approves New Obesity Pill – Health System Under Strain
Published on 07/20/2026 at 11:51 | Redaktion boerse-global.de
An acute shortfall of roughly 74,000 medication packs across Austria is putting patients at risk, with drugs for the nervous system hardest hit. New data from July 2026 show that about one in every ten citizens relies annually on medicines now classified as critically scarce. Nearly a third – 33 percent – of all active ingredients flagged as supply-sensitive belong to the psychopharmaceutical category, a situation that complicates daily care and leaves clinicians scrambling for alternatives.
The supply crisis unfolds even as the European Union greenlights a novel oral therapy for obesity. On 15 July 2026, the European Commission approved a 25-milligram tablet form of semaglutide for use across all 27 member states and the European Economic Area. Clinical trials have recorded an average weight loss of around 17 percent among patients taking the drug. Demand is expected to spike, mirroring the surge seen in other markets shortly after similar products launched.
Also new on the German market is the Dexcom Flex system, a continuous glucose monitoring (CGM) device for adults with type 2 diabetes who do not require intensive insulin therapy. The system transmits glucose readings in real time to a smartphone app, reducing the need for traditional finger-prick tests. Health insurers are evaluating coverage on a case-by-case basis.
Despite these therapeutic advances, the underlying fragility of the pharmaceutical supply chain remains stark. Since April 2025, stricter storage rules have required wholesalers to hold a four-month stock of the 400 highest-revenue product packs. Whether that mandate is sufficient is open to question, given the ongoing gaps.
Compounding the strain is a government austerity package. Germany’s black-red coalition has drawn up spending curbs to close a projected €18.8 billion financing hole for 2027. The aim is to keep the average supplementary health insurance contribution rate stable at 2.9 percent, down from the current 3.1 percent. The package imposes brakes on expenditure for hospitals, the pharmaceutical industry, and pharmacies alike. Insurers’ associations describe the plan as a foundation for stable premiums over the next two years.
Legal complexities over discount models add another layer. Germany’s Federal Court of Justice has ruled that price reductions on medicines sourced from abroad are permissible only for non-prescription drugs. For prescription products, such discounts remain prohibited under existing price regulations.
Telemedicine, by contrast, is gaining ground despite the bottlenecks. Providers such as TeleClinic report robust growth, particularly among patients over 65. More than four million video consultations have been conducted so far. In a collaboration with the Kassenärztliche Vereinigung Niedersachsen (the statutory physician association of Lower Saxony), over 100,000 treatments were delivered, 80 percent of them completed entirely via telemedicine. Electronic prescriptions and digital distribution channels are becoming increasingly important, especially where local pharmacies face shortages or budget constraints.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
